Meiji Yasuda Life Insurance Co Increases Position in Medtronic PLC $MDT

Meiji Yasuda Life Insurance Co lifted its stake in Medtronic PLC (NYSE:MDT) by 43.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,191 shares of the medical technology company’s stock after purchasing an additional 7,278 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Medtronic were worth $1,892,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MDT. Thornburg Investment Management Inc. grew its position in Medtronic by 24.5% during the second quarter. Thornburg Investment Management Inc. now owns 2,511,730 shares of the medical technology company’s stock worth $196,493,000 after buying an additional 494,653 shares during the period. Hennessy Advisors Inc. increased its holdings in Medtronic by 50.5% in the second quarter. Hennessy Advisors Inc. now owns 90,326 shares of the medical technology company’s stock valued at $7,066,000 after buying an additional 30,326 shares in the last quarter. Sheets Smith Wealth Management acquired a new stake in shares of Medtronic during the 2nd quarter valued at approximately $387,000. Spinnaker Trust lifted its position in shares of Medtronic by 15.2% during the 2nd quarter. Spinnaker Trust now owns 69,721 shares of the medical technology company’s stock valued at $5,454,000 after acquiring an additional 9,186 shares during the period. Finally, Greenwood Capital Associates LLC boosted its stake in shares of Medtronic by 28.0% during the 2nd quarter. Greenwood Capital Associates LLC now owns 84,156 shares of the medical technology company’s stock worth $6,584,000 after acquiring an additional 18,407 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of research reports. Truist Financial lowered their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a report on Thursday, June 4th. Stifel Nicolaus set a $80.00 price objective on Medtronic in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft decreased their target price on Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Needham & Company LLC upped their target price on Medtronic from $101.00 to $114.00 and gave the company a “buy” rating in a report on Thursday. Finally, Rothschild & Co Redburn dropped their price target on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.79.

Medtronic Stock Up 1.5%

MDT opened at $91.28 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a market cap of $116.84 billion, a P/E ratio of 24.47, a PEG ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The business’s fifty day simple moving average is $85.57 and its 200 day simple moving average is $85.67.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter last year, the business posted $1.62 EPS. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s payout ratio is 77.21%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by company insiders.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).